# Immunophage

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunophage

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.immunophage.com.cn
- Total disclosed funding: $76M
- Latest round: Series B (Mar 13, 2023)
- Investors on record: 8

## About

Based in Nanjing, China,  Nanjing and founded in 2016, Nanjing Immunophage Biomedical Co.,Ltd, dba Immunophage, operates as a medical company that engages in developing drugs for the treatment of malignant tumors, autoimmune diseases, metabolic diseases and neurodegenerative diseases. The core team of the company is composed of former GSK executives. The company's founder, Dr. Guohuang Fan, once managed the new drug R&D team at GSK China R&D Center. In 2018, it established the Shanghai R&D Center Amed Medical Technology (Shanghai) Co., Ltd. Immunophage has subsidiaries in Australia and the United States. In August 2025, Immunophage closed a venture funding from new investors Beijing New Medical Consulting, Zhoushan Hengkun Medical, Winfund Investment and returning investor Ennovation Ventures.

The company's main business is the research and development of targeted drugs. In the field of oncology, it focuses on developing new immunomodulatory anti-tumor drugs to reverse the tumor immunosuppressive microenvironment. In the field of autoimmune diseases, metabolic diseases and neurodegenerative diseases, the company focuses on pathological changes caused by innate immune inflammation to develop new drugs.

The company generates revenue by developing medicines against cancer, autoimmune diseases, neurodegenerative disorders.

## Funding rounds

- Series B, Mar 13, 2023, $29M — Zbjl Capital
- Series A, Sep 29, 2021, $16M — MED-FINE Capital, Yijing Investment, Tao Capital, Renjin Capital
- Series A, May 11, 2021, $31M — NSR Wealth Management, Shanghai Junshi Biosciences Co., Ltd., LC Ventures

## Investors

- NSR Wealth Management (https://capitalatlas.ai/funds/nsr-wealth-management) — Series A
- Shanghai Junshi Biosciences Co., Ltd. — Series A
- LC Ventures (https://capitalatlas.ai/funds/lc-ventures) — Series A
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series A
- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Series A
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series A
- Renjin Capital (https://capitalatlas.ai/funds/renjin-capital) — Series A
- Zbjl Capital (https://capitalatlas.ai/funds/zbjl-capital) — Series B